SH3GL2

Across TCGA pan-cancer cohorts, SH3GL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH3GL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SH3GL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SH3GL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SH3GL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.440	0.224	.004	52	view →
CCRCC	OS	Median	All	1.000	0.909	.019	6	view →
LUAD	OS	Tertile	All	0.972	1.000	.037	4	view →
UCEC	OS	Tertile	II,III,IV	0.464	0.811	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH3GL2–PDAC (OS)

Open the PDAC breakdown →